Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle
Medicinal Research Reviews · 2024
DOI: 10.1002/med.22023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2024. Verfasst von Mojtaba Taheri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Bioengineering, Neoplasms, Nanotechnology. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 388 Literaturangaben. Gefördert von: Tarbiat Modares University, Mashhad University of Medical Sciences.
Abstract (Originalsprache)
Targeting actionable mutations in oncogene‐driven cancers and the evolution of immuno‐oncology are the two prominent revolutions that have influenced cancer treatment paradigms and caused the emergence of precision oncology. However, intertumoral and intratumoral heterogeneity are the main challenges in both fields of precision cancer treatment. In other words, finding a universal marker or pathway in patients suffering from a particular type of cancer is challenging. Therefore, targeting a single hallmark or pathway with a single targeted therapeutic will not be efficient for fighting against tumor heterogeneity. Mesenchymal stem cells (MSCs) possess favorable characteristics for cellular therapy, including their hypoimmune nature, inherent tumor‐tropism property, straightforward isolation, and multilineage differentiation potential. MSCs can be loaded with various chemotherapeutics and oncolytic viruses. The combination of these intrinsic features with the possibility of genetic manipulation makes them a versatile tumor delivery vehicle that can be used for in vivo selective tumor delivery of various chemotherapeutic and biological therapeutics. MSCs can be used as biofactory for the local production of chemical or biological anticancer agents at the tumor site. MSC‐mediated immunotherapy could facilitate the sustained release of immunotherapeutic agents specifically at the tumor site, and allow for the achievement of therapeutic concentrations without the need for repetitive systemic administration of high therapeutic doses. Despite the enthusiasm evoked by preclinical studies that used MSC in various cancer therapy approaches, the translation of MSCs into clinical applications has faced serious challenges. This manuscript, with a critical viewpoint, reviewed the preclinical and clinical studies that have evaluated MSCs as a selective tumor delivery tool in various cancer therapy approaches, including gene therapy, immunotherapy, and chemotherapy. Then, the novel nanotechnology and bioengineering approaches that can improve the potency of MSC for tumor targeting and overcoming challenges related to their low localization at the tumor sites are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
- Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran.
- Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Mohammad Ramezani
Förderung
- Tarbiat Modares University
- Mashhad University of Medical Sciences
Zitieren
APA
Taheri, M., Tehrani, H. A., Dehghani, S., Alibolandi, M., Arefian, E., & Ramezani, M. (2024). Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle. Medicinal Research Reviews. https://doi.org/10.1002/med.22023
Vancouver
Taheri M, Tehrani HA, Dehghani S, Alibolandi M, Arefian E, Ramezani M. Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle. Medicinal Research Reviews. 2024. doi:10.1002/med.22023
BibTeX
@article{Taheri2024,
author = {Taheri, Mojtaba and Tehrani, Hossein Abdul and Dehghani, Sadegh and Alibolandi, Mona and Arefian, Ehsan and Ramezani, Mohammad},
title = {Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle},
journal = {Medicinal Research Reviews},
year = {2024},
doi = {10.1002/med.22023}
}
EUVIMED